Corporate ProfileCytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology.
Stock InformationNASDAQ: CTMX$21.57 Stock is Down 0.09 (0.42%)
Recent Webcast
DateTitle
11/15/17 11:40 a.m. ET
CytomX Therapeutics Inc at Jefferies 2017 London Healthcare Conference
Recent Presentation
DateTitle
11/14/17
Download Documentation  CTMX Corporate Presentation November 2017
Recent News

More >>

Data provided by Nasdaq. Minimum 15 minutes delayed.